IQVIA software bridges the gap between life sciences companies and patients

IQVIA™ (NYSE: IQV) has announced the launch of Orchestrated Patient Engagement (OPE), a new cloud-based software as a service (SaaS) solution that helps close the gap between life sciences companies and patients, the company said.

The OPE SaaS solution is powered by Belong.Life technology to allow life sciences customers to facilitate interactions and gain insights from patients who opt-in, assisting in the commercialization process.

IQVIA´s OPE creates unique advantages and drives value throughout the commercialization process. For instance, OPE provides access to information for patients during the pre-launch phase, empowering life sciences customers to develop a deep understanding of patient needs. At launch, OPE delivers hyper-targeted awareness campaigns to patients who joined the program. For existing marketed therapies, OPE facilitates direct engagement to understand compliance patterns and drive adherence.

IQVIA OPE is designed to protect patients´ data and provide transparency for its users, by involving patients in decisions about how their information might be used throughout the patient journey. Patients can choose to join and opt-out at any time. IQVIA OPE will be available in the United States in the fourth quarter of 2019.

Founded in 2015 by noted entrepreneurs Eliran Malki, Irad Deutsch and Ohad Rubin after each lost relatives to cancer, Belong – Beating Cancer Together is a free patient navigation app that allows cancer patients and their support network to explore and better manage their treatment journey while improving their quality of life. To learn more, visit

IQVIA (NYSE:IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.